The FDA approved a new drug for treating autoimmune neuropathies on September 9, 2025, accompanied by discoveries of new autoantibodies and effective complement inhibitors. This development ends 30 years of limited treatment progress in the field.

Breakthrough Details

According to a post on X by @geeknik, new autoantibodies have been identified, and complement inhibitors are showing promising results. The approval represents a major step forward in managing these conditions.

Significance

As stated in the X post, this ends a long period of stagnation in treatments for autoimmune neuropathies.

Information based on posts found on X.